ARCA biopharma Inc
For the period ended Dec 31, 2023. Filed Feb 1, 2024.
View on SEC.govAbout this filing
A company's yearly report to the SEC, with audited financial statements. It is the fullest account a company gives of its business, its finances and the risks it sees.
FY2023 · Filed Feb 1, 2024
ORKA$104.56+1.7%Stored close · as of Nov 9, 2026
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
STATEMENTS OF STOCKHOLDERS’ EQUITY
| Stockholders’ Equity | |||||
|---|---|---|---|---|---|
| Additional | |||||
| Common stock · Paid-In · Accumulated | |||||
| Shares | Amount | Capital | Deficit | Total | |
| (in thousands, except share and per share amounts) | |||||
| Balance, December 31, 2021 | 14,410,143 | $14 | $224,505 | $(173,476) | $51,043 |
| Share-based compensation | — | — | 556 | — | 556 |
| Net loss | — | — | — | (9,926) | (9,926) |
| Balance, December 31, 2022 | 14,410,143 | 14 | 225,061 | (183,402) | 41,673 |
| Issuance of common stock upon vesting of Restricted Stock Units | 91,000 | — | — | — | — |
| Share-based compensation | — | — | 686 | — | 686 |
| Net loss | — | — | — | (5,339) | (5,339) |
| Balance, December 31, 2023 | 14,501,143 | $14 | $225,747 | $(188,741) | $37,020 |
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.